pubmed.ncbi.nlm.nih.gov

The treatment of anti-phospholipid syndrome: A comprehensive clinical approach - PubMed

Review

The treatment of anti-phospholipid syndrome: A comprehensive clinical approach

Cecilia Beatrice Chighizola et al. J Autoimmun. 2018 Jun.

Abstract

Anti-phospholipid syndrome (APS) is an acquired pro-thrombotic autoimmune disease that predisposes to thrombotic events and/or obstetric complications, in the persistent presence of anti-phospholipid antibodies (aPL). Life long moderate-intensity anticoagulation is the option of choice for aPL-positive patients with a previous thrombosis; critical issues concern the management of those with a history of arterial event due to the high rate of recurrence. Alternatives comprise anti-platelet agents and high-intensity anticoagulation. Low dose aspirin (LDASA) and low molecular weight heparin provide the mainstay of the treatment of obstetric APS, allowing a birth rate in 70% of cases. The management of refractory APS, thrombotic as well as obstetric, is highly debated, but an increasing burden of evidence points towards the beneficial effects of multiple treatments. Similarly, a management envisaging multiple drugs (anticoagulation, steroids, plasma exchange and/or intravenous immunoglobulins) is the most effective approach in catastrophic APS. Asymptomatic aPL carriers are at higher risk of thrombotic and obstetric complications compared to the general population, thus potentially benefitting of a pharmacological intervention. LDASA and hydroxychloroquine can be considered as options, in particular in case of high risk aPL profile, concomitant cardiovascular risk factors or associated autoimmune disease. APS is apparently a simple condition, but its multifaceted nature requires a complex and tailored treatment.

Keywords: Anti-phospholipid antibodies; Anti-phospholipid syndrome; Asymptomatic carriers; Catastrophic anti-phospholipid syndrome; Obstetric complications; Thrombosis.

PubMed Disclaimer

Cited by

Development of a risk prediction model for the first occurrence of thrombosis in patients with OAPS.
Gao J, Zheng Y, Wang Z, Jia J, Wan J, Han Q, Zheng X, Liu R, Zheng Z, Wu K, Zhu P. Gao J, et al. Front Immunol. 2024 Oct 4;15:1459548. doi: 10.3389/fimmu.2024.1459548. eCollection 2024. Front Immunol. 2024. PMID: 39430748 Free PMC article.
Exploring the Complexities of Non-Bacterial Thrombotic Endocarditis: Highlights from Literature and Case Studies.
Santarpino G, Lofrumento F, Zito C, Trio O, Restelli D, Cusmà Piccione M, Manganaro R, Carerj S, Cardetta F, Fiore C, de Gregorio C. Santarpino G, et al. J Clin Med. 2024 Aug 20;13(16):4904. doi: 10.3390/jcm13164904. J Clin Med. 2024. PMID: 39201046 Free PMC article. Review.
Risk factors of first thrombosis in obstetric antiphospholipid syndrome.
Luo L, Cai Q, Liu X, Hou Y, Li C. Luo L, et al. Lupus Sci Med. 2024 Jan 3;11(1):e001044. doi: 10.1136/lupus-2023-001044. Lupus Sci Med. 2024. PMID: 38176700 Free PMC article.
Obstetric Anti-phospholipid Syndrome: State of the Art.
Gerardi MC, Fernandes MA, Tincani A, Andreoli L. Gerardi MC, et al. Curr Rheumatol Rep. 2018 Aug 13;20(10):59. doi: 10.1007/s11926-018-0772-y. Curr Rheumatol Rep. 2018. PMID: 30105597 Review.
Dorsolateral medullary infarction during skin infection by Stenotrophomonas maltophilia in a patient with triple antiphospholipid antibody positivity: a case-based review.
Chen YL, Yang HT, Liu LX, Chen CH, Huang Q, Hong XP, Zhao JL, Liu DZ. Chen YL, et al. Clin Rheumatol. 2021 Jul;40(7):2965-2971. doi: 10.1007/s10067-020-05489-3. Epub 2020 Nov 5. Clin Rheumatol. 2021. PMID: 33155156 Free PMC article. Review.

The treatment of anti-phospholipid syndrome: A comprehensive clinical approach - PubMed